Immune checkpoint inhibitors have garnered substantial attention as a therapeutic strategy, with notable immune checkpoints, including CTLA4, PD-1, PD-L1, and LAG3, identified as effective targets for stimulating T cell-mediated anti-tumor immunity (67). Here, LAG3 is linked to neoplasm.